Background: This study was conducted to investigate the
relationship between clinical course and pulmonary artery (PA) diameters
in children diagnosed with COVID-19. Method: The study included 62
patients who presented COVID-19 symptoms between March 2020 and April
2021. Group 1 consisted of 32 pediatric patients who were COVID-19 PCR
(+), while Group 2 consisted of 30 pediatric patients who were COVID-19
PCR(-). The data were collected retrospectively from medical records.
Patients who developed pneumonia due to causes other than COVID-19 and
those who had a history of pulmonary hypertension or pulmonary
thromboembolism were excluded. The patients were examined based on their
Computerized Tomographic (CT) findings, simultaneous whole blood
parameters and biochemical parameters. Results: The thoracic CT findings
of 18 of the patients in Group 1 were found normal. The CT images of 14
patients showed pulmonary involvement. Among the patients with pulmonary
involvement, 8 had moderate pneumonia characterized by a ground-glass
pattern, and 6 had severe pneumonia indicated by consolidation and
linear opacities. The right pulmonary artery, left pulmonary artery and
inferior vena cava (IVC) diameters of the patients in Group 1 were
significantly higher than those of the patients in Group 2. Conclusion:
The results of this study suggested that increased PA diameters in
children diagnosed with COVID-19 may be accompanied by increased
inflammation, high vascular resistance, hypoxemia and thromboembolic
events. While it is thought that increased PA and IVC diameters are a
factor that may indicate clinical deterioration in COVID-19 patients,
more comprehensive studies are needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.